Gongwin-KY’s skin topical series formula hand in hand with Australian beauty factory to develop facial mask products
Gongwin-KY (6617) today announced that its business transformation has taken its first step. Recently, Gongwin signed a memorandum of cooperation with a well-known Australian cosmetics manufacturer to authorize its Australian partners to use GW-1205 formula in the development and global sales of its makeup product series, aiming to seize business opportunities in the global beauty and skin care products market.
Gongwin Biopharm’s collaboration model this time is adopted by exporting GW-1205 raw materials from Taiwan Gongwin, and various semi-finished products or end products will be made by its Australian partners. In addition to receiving technical licensing fees from its Australian partners, Gongwin will also receive sales revenues from GW-1205 formula raw materials. When the customers’ demands continue to increase in the future, this will bring positive contributions to Gongwin’s overall operations.
Gongwin-KY stated that its GW-1205 is a formula developed by Taiwan Gongwin Biopharm. As early as the end of 2017, it applied for a patent case number: US15/858,617 to the United States Patent and Trademark Office. According to the evidence of tests which were entrusted by Gongwin for Eurofins Group‘sPHARMACOLOGY DISCOVERY SERVICES TAIWAN, LTD. and SGS to conduct, it was proved that GW-1205 can effectively inhibit the growth of acne bacillus and staphylococcus epidermidis. In the cell anti-inflammatory model experiment, it was verified that GW-1205 could effectively inhibit the secretion of inflammatory factors (TNF-α). The data is sufficient to illustrate that GW-1205 does have antibacterial and anti-inflammatory characteristics.
Gongwin-KY’s Australian partner is optimistic about the uniqueness and competitiveness of GW-1205 in the market, and after completing the irritation and sensitivity tests of its beauty products using GW-1205 as the base material, they recently signed a memorandum of cooperation with Gongwin-KY. The initial stage of the collaboration will focus on facial mask series products, expected to create a new trend in the beauty and skin care market.
Gongwin-KY is optimistic that there may be an opportunity for its skin topical products to become the cash cow, a source of stable revenue, for the group's operations. At present, in addition to co-accelerating the development of facial mask series with its Australian partner, Gongwin is also continuing to speed up the development and certification related application of GW-1205. Following other types of beauty products starting mass production, it will help drive the sales of Gongwin-KY’s raw materials to increase.
In addition, the progress of Gongwin-KY’s business transformation strategy is on the go, in order to expand the global market share of GW-1205 and continue to strive for collaboration opportunities with more skin-related topical manufacturers around the globe, aiming to contribute to the company's excellent overall operational performance.
Looking forward to the future, the beauty end products made of Gongwin-KY‘s GW-1205 raw materials will start its sale in 2019 the earliest. At the same time, Gongwin is actively constructing a research and development center and a trial mass production line in Wugu Industrial Park in New Taipei City. The construction is expected to be completed and for Gongiwn to settle in around the middle of next year. As for overseas sales and transnational clinical deployment, Gongwin-KY is actively deploying clinical trial applications in the United States, New Zealand and Australia to strive to have the clinical trials application of new drug PTS-02 for the treatment of adenoid cystic carcinoma submitted to multi-centers in the United States in the first half of 2019, creating a complete global treatment and sales deployment.
News link URL：https://finance.ettoday.net/news/1317947#ixzz6vvlP0I4Z
News&Media